<DOC>
	<DOCNO>NCT02975037</DOCNO>
	<brief_summary>Evaluation validation metabolic marker prediction drug-drug interaction various CYP3A4 substrate ( sildenafil ) inhibitor ( erythromycin/itraconazole ) healthy male subject</brief_summary>
	<brief_title>Evaluation Metabolic Markers Prediction DDI Various CYP3A Substrates Inhibitors</brief_title>
	<detailed_description>Subjects suitable study admit Clinical Trials Center , Seoul National University Hospital day dose , overnight-fasted 9P Day -1 . Urine collection schedule 12 hour sildenafil administration 12 hour administration . Subjects administer sildenafil ( oral ) around 9A Day 1 . Subjects perform schedule procedure include clinical laboratory test , electrocardiogram blood sampling pharmacokinetic , pharmacometabolomic mRNA assessment . Subjects administer either erythromycin itraconazole ( oral ) around 9A Day 3 9A/9P Day 4 . Urine collection schedule 0 hour 12 hour Day 3 erythromycin itraconazole administration . Subjects perform schedule procedure include clinical laboratory test , electrocardiogram blood sampling pharmacokinetic , pharmacometabolomic mRNA assessment . On Day 5 , sildenafil administer erythromycin itraconazole around 9A . Urine collection schedule 12 hour Day 5 drug administration 12 hour administration . Subjects perform schedule procedure . After subject perform schedule procedure , study discharge ( around 9A Day 6 ) . Study participation terminate post-study visit ( Day 12-14 ) .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Age : Between 19 50 year age , inclusive Weight : within 1728 Body Mass Index ( BMI ) Subject reliable willing make available study period . Subject willing follow study protocol , give write informed consent voluntarily . History hypersensitive reaction medication ( midazolam , itraconazole , rifampicin ) History significant clinical illness need medical caution , include cardiovascular , immunologic , hematologic , neuropsychiatric , respiratory , gastrointestinal , hepatic , renal disease chronic disease History evidence drug abuse Use prescriptive medication , Korean traditional medication consider acceptable clinical investigator last 14 day period first dose , use medication consider acceptable clinical investigator last 7 day period first dose ( use medication consider acceptable investigator , patient include ) Participation clinical trial drug within 3 month prior participation study Judged inappropriate study investigator</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>